The Need for Comprehensive Care for Persons with Chronic Immune Thrombocytopenic Purpura

References

• Tarantino MD, Goldsmith G. Treatment of acute immune thrombocytopenic purpura. Sem Hem. 1998;35(1):28–35.
   Web of Science ®Google Scholar
• Jones HW, Tocantins LM. The history of purpura hemorrhagica. Ann Med Hist. 1933;5:349–359.
   Google Scholar
• Frommeyer WB, Epstein RD, Taylor FHL. Refractoriness in hemophilia to coagulation-promoting agents: whole blood and plasma derivatives. Blood. 1950;5(5):401–420. doi:10.1182/blood.V5.5.401.40115414197
   PubMed Web of Science ®Google Scholar
• Kasnelson P. Verschwinden der hamorrhagischen diathese bei einem falle von “essentieller thrombopenia” nach Milzexstirpation: splenogene thrombolytische purpura. Wien Klin Wochenschr. 1916;29:1451–1454.
   Google Scholar
• Aggeler PM, White SG, Glendening MB, et al. Plasma thromboplastin component (PTC) deficiency: a new disease resembling hemophilia. Proc Soc Exp Biol Med. 1952;79:692–694. doi:10.3181/00379727-79-1948814920537
   PubMed Web of Science ®Google Scholar
• Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965;124:499–542. doi:10.1111/j.1749-6632.1965.tb18984.x5214832
   PubMed Web of Science ®Google Scholar
• Pool JG. Cryoprecipitate in the treatment of hemophilia. Calif Med. 1970;113(2):66–67.
   Google Scholar
• Dameshek W, Rubio F, Mahoney JP, et al. Treatment of idiopathic thrombocytopenic purpura (ITP) with prednisone. JAMA. 1958;166:1805–1815. doi:10.1001/jama.1958.02990150001001
   PubMed Web of Science ®Google Scholar
• Kasper CK. Judith Graham Pool and the discovery of cryoprecipitate. Haemophilia. 2012;18:833–835. doi:10.1111/hae.1204223106944
   PubMed Web of Science ®Google Scholar
• Kernoff PB, Lee CA, Karayiannis P, et al. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol. 1985;60(3):469–479. doi:10.1111/j.1365-2141.1985.tb07444.x3925981
   PubMed Web of Science ®Google Scholar
• Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other disease. Swiss Med Wkly. 2012;142(w13593):1–10.
   Google Scholar
• Aledort L, Mannucci MP, Schramm W, Tarantino MD. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion. 2019;17:479–486.31846611
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818. doi:10.1056/NEJMoa170306828691557
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients with hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811–822. doi:10.1056/NEJMoa180355030157389
   PubMed Web of Science ®Google Scholar
• Pasi JK, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819–828. doi:10.1056/NEJMoa161656928691885
   PubMed Web of Science ®Google Scholar
• Spencer HT, Riley BE, Doering CB. State of the art: gene therapy of haemophilia. Haemophilia. 2016;22(Suppl. 5):66–71. doi:10.1111/hae.1301127405679
   PubMed Web of Science ®Google Scholar
• Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood. 2019;133(5):407–414. doi:10.1182/blood-2018-07-82072030559260
   PubMed Web of Science ®Google Scholar
• Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952–957. doi:10.1182/blood.V98.4.95211493438
   PubMed Web of Science ®Google Scholar
• Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146:585–596. doi:10.1111/j.1365-2141.2009.07717.x19466980
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Chalmers S. Therapeutic thrombopoietin mimetics In: Gresele P, Kleiman NS, Lopez JA, Page CP, editors. Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics. 2nd ed. Cambridge University Press; 2016:1417–1429.
   Google Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two Phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93:921–930. doi:10.1002/ajh.2512529696684
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Bolton-Maggs PHB, Soucie M, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2009;16(1):20–32. doi:10.1111/j.1365-2516.2009.02127.x
   Web of Science ®Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Int Med. 2019;171(8):1–9. doi:10.7326/M19-120831158849
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Data & statistics on hemophilia; 2019 Para 1–2 Available from: https://www.cdc.gov/ncbddd/hemophilia/data.html. Accessed 1208, 2020
   Google Scholar
• Biere-Rafi S, Baarslag MA, Peters M, et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost. 2011;105:274–278. doi:10.1160/TH10-07-046021136012
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Throm Haemost. 2006;4(11):2377–2383. doi:10.1111/j.1538-7836.2006.02147.x
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;2(22):3780–3817.
   Web of Science ®Google Scholar
• Boral LI, Monohan GP, Moirangthem V. Overview of adult immune thrombocytopenia. Pathol Lab Med. 2016;1(1):21–31.
   Google Scholar
• Terrell DR, Beebe LA, Vesely SK. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–180.20131303
   PubMed Web of Science ®Google Scholar
• Van Den Berg HM, De Groot PHG, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007;5(S1):151–156. doi:10.1111/j.1538-7836.2007.02503.x17635721
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 2nd ed. Montreal (Que.): World Federation of Hemophilia; 2012.
   Google Scholar
• Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenia purpura. Blood. 1991;77(1):31–33. doi:10.1182/blood.V77.1.31.311984800
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630–1638. doi:10.1001/archinte.160.11.163010847256
   PubMed Web of Science ®Google Scholar
• Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372–1382. doi:10.1111/j.1538-7836.2010.03830.x20230419
   PubMed Web of Science ®Google Scholar
• Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenic purpura (ITP): study of 40 cases. Blood. 2009;114:4777–4783. doi:10.1182/blood-2009-04-21552519767509
   PubMed Web of Science ®Google Scholar
• O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):1–8. doi:10.1186/s12955-018-0908-929291738
   PubMed Web of Science ®Google Scholar
• Mathias SD, Gau SK, Miller KL. Impact of immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes. 2008;6(1):1–14. doi:10.1186/1477-7525-6-1318179687
   PubMed Web of Science ®Google Scholar
• Efficace F, Mandeilli F, Fazi P. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hem. 2016;91(10):995–1001. doi:10.1002/ajh.24463
   PubMed Web of Science ®Google Scholar
• Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer. 2016;63:1232–1237. doi:10.1002/pbc.2598427037553
   PubMed Web of Science ®Google Scholar
• Evatt BL, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. Haemophilia. 2004;10(Suppl s4):9–13. doi:10.1111/j.1365-2516.2004.01010.x
   PubMed Web of Science ®Google Scholar
• Ruiz-Sa´ez A. Comprehensive care in haemophilia. Hematology. 2012;17(sup1):S141–S143. doi:10.1179/102453312X1333616915649222507803
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs P. Optimal haemophilia care versus the reality. Br J Haematol. 2005;132(6):671–682. doi:10.1111/j.1365-2141.2005.05952.x
   Web of Science ®Google Scholar
• National Hemophilia Foundation; n.d. Available from: https://www.hemophilia.org/. Accessed 1208, 2020
   Google Scholar
• World Federation of Hemophilia. Vision and mission; n.d. Available from: https://www.wfh.org/en/about/vision-and-mission. Accessed 1208, 2020
   Google Scholar
• Soucie M, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. Blood. 2000;96(2):437–442.10887103
   PubMed Web of Science ®Google Scholar
• Okolo AI, Soucie JM, Grosse SD, et al. Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources. Haemophilia. 2019;25(3):456–463. doi:10.1111/hae.1373430924993
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Mathias SD, Snyder CF, et al. Impact of ITP on physician visits and workplace productivity. Cur Med Res Opin. 2010;26(2):319–328. doi:10.1185/03007990903451298
   PubMed Web of Science ®Google Scholar
• Platelet Disorder Support Association; n.d. Available from: https://www.pdsa.org/. Accessed 1208, 2020
   Google Scholar